Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Lauren Lenz"'
Autor:
Jack M. Cuzick, Steven Stone, Lauren Lenz, Darl D. Flake, Saradha Rajamani, Henrik Moller, Daniel Maurice Berney, Todd Cohen, Peter T. Scardino
Publikováno v:
Cancer Reports, Vol 5, Iss 8, Pp n/a-n/a (2022)
Abstract Background Validation of biomarker‐based prognostic models to improve risk stratification in men with localized prostate cancer (PrCa) remains a clinical need. It has previously been shown that the cell cycle progression (CCP) test provide
Externí odkaz:
https://doaj.org/article/7a27c92123b54b92a8b9551cefb4fd0c
Autor:
Bruce J. Trock, Yuezhou Jing, Brent Mabey, Zaina Sangale, Lauren Lenz, Nora Haney, Igor Vidal, Stephanie A. Glavaris, Gunes Guner, Onur Ertunc, Ibrahim Kulac, Javier A. Baena Del Valle, Tracy Jones, Misop Han, Alan W. Partin, Todd Cohen, Steven Stone, Angelo M. De Marzo
Publikováno v:
Journal of Urology. 208:1182-1193
The prognostic value for metastasis of the cell-cycle progression score and phosphatase and tensin homolog haven't been evaluated jointly in contemporary men with exclusively intermediate- or high-risk prostate cancer. We evaluated associations of ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcc380b5ee60f8f28a37f0361fded189
https://doi.org/10.1097/ju.0000000000002922
https://doi.org/10.1097/ju.0000000000002922
Autor:
Vanessa Kuhl, Wyatt Clegg, Stephanie Meek, Lauren Lenz, Darl D Flake, Tracy Ronan, Max Kornilov, Deborah Horsch, Marsel Scheer, Daniel Farber, Hillary Zalaznick, Olivier Cussenot, Eva Compérat, Geraldine Cancel-Tassin, Peter J Wild, Felix KH Chun, Philipp Mandel, Farid Moinfar, Todd Cohen, Sylvette Delee, Ralf Kronenwett, Jennifer Doedt
Publikováno v:
Biomarkers in Medicine. 16:449-459
Aim: The 46-gene Prolaris® cell cycle progression test provides information on the risk of prostate cancer progression. Here we developed and validated a 16-gene kit-based version. Methods: RNA was extracted from prostate cancer biopsy tissue. Ampli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9221b626ba4da981a90d2da19496401c
https://doi.org/10.2217/bmm-2021-0479
https://doi.org/10.2217/bmm-2021-0479
Autor:
Kirsten M Timms, Lauren Lenz, Chris Neff, Cara Solimeno, Darl Flake, Judy C Boughey, Matthew P Goetz, Andrea Richardson, Anna Maria Storniolo, Alexander Gutin, Roisin M Connolly, Vered Stearns, Jerry S Lanchbury
Publikováno v:
Cancer Research. 82:P5-13
Background: Patients with homologous recombin ation (HR) deficient tumors may benefit from treatment with DNA damaging agents. Markers of genomic instability can be used to identify HR deficiency, including a 3-biomarker Genomic Instability Score (GI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28e2b9b81aa32d830b2f3bab3dcc5811
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-09
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-09
Autor:
Bruce J. Trock, Yuezhou Jing, Brent Mabey, Zaina Sangale, Lauren Lenz, Nora Haney, Igor Vidal, Stephanie A. Glavaris, Gunes Guner, Onur Ertunc, Ibrahim Kulac, Javier A. Baena Del Valle, Tracy Jones, Misop Han, Alan W. Partin, Todd Cohen, Steven Stone, Angelo M. De Marzo
Publikováno v:
The Journal of urology. 208(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052b401b70934f1f327246c38adf36ca
https://pubmed.ncbi.nlm.nih.gov/36349916
https://pubmed.ncbi.nlm.nih.gov/36349916
Autor:
Jonathan Tward, Lauren Lenz
Publikováno v:
International journal of radiation oncology, biology, physics. 115(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::febebabb338f8b9b14fe5eb24eba6314
https://pubmed.ncbi.nlm.nih.gov/36526395
https://pubmed.ncbi.nlm.nih.gov/36526395
Autor:
Saradha Rajamani, Todd Cohen, Lauren Lenz, Steven Stone, Daniel M. Berney, Peter T. Scardino, Henrik Møller, Darl D. Flake, Jack Cuzick
Publikováno v:
Cancer Reports. 5
Background Validation of biomarker-based prognostic models to improve risk stratification in men with localized prostate cancer (PrCa) remains a clinical need. It has previously been shown that the cell cycle progression (CCP) test provides significa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80c8aef138694b90d6b5e6a15bce6870
https://doi.org/10.1002/cnr2.1535
https://doi.org/10.1002/cnr2.1535
Autor:
Adam Brufsky, Lauren Lenz, Anita Pudusseri, David Wright, Kashyap B. Patel, Brad T. Clifford, Tracey L. O'Connor, Sasha Strain, Fadi Kayali, Sarah Ratzel, Shelly Cummings, Ralf Kronenwett, Thomas Paul Slavin
Publikováno v:
Journal of Clinical Oncology. 40:537-537
537 Background: Current guidelines advise that individuals with estrogen receptor-positive (ER+) breast cancer (BC) undergo 5 years of endocrine therapy with consideration of up to 10 years of extended endocrine therapy (EET). The relative benefit of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6af587c8ff15d7a0b771064900ee6582
https://doi.org/10.1200/jco.2022.40.16_suppl.537
https://doi.org/10.1200/jco.2022.40.16_suppl.537
Autor:
Kirsten Timms, Lauren Lenz, Elizabeth S. Cogan, Erica L. Mayer, Virginia G. Kaklamani, Vered Stearns, Vandana G Abramson, Carla Isadora Falkson, Rachel Catherine Jankowitz, P. Kelly Kelly Marcom, Nadine M. Tung, William John Gradishar, James M. Ford, Shaveta Vinayak, Judy Caroline Boughey, Matthew P. Goetz, Anna Maria Storniolo, Roisin M. Connolly, Andrea L. Richardson, Melinda L. Telli
Publikováno v:
Journal of Clinical Oncology. 40:525-525
525 Background: Homologous recombination deficiency (HRD) status can be used to identify patients who are eligible for treatment with DNA damaging agents. Using a 3-biomarker Genomic Instability Score (GIS) threshold of ≥42, studies have previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d20296c0829e64d68c5440dfd2addaeb
https://doi.org/10.1200/jco.2022.40.16_suppl.525
https://doi.org/10.1200/jco.2022.40.16_suppl.525
Autor:
Jonathan Tward, Lauren Lenz, Darl D. Flake, Saradha Rajamani, Paul Yonover, Carl Olsson, Deepak A. Kapoor, Constantine Mantz, Stanley L. Liauw, Tatjana Antic, Michael Fabrizio, Daniel Salzstein, Neal Shore, Dan Albertson, Jonathan Henderson, Steve P. Lee, Hiram A. Gay, Jeff Michalski, Arthur Hung, David Raben, Isla Garraway, Michael S. Lewis, Paul L. Nguyen, David T. Marshall, Michael K. Brawer, Steven Stone, Todd Cohen
Publikováno v:
International journal of radiation oncology, biology, physics. 113(1)
PURPOSE The clinical cell-cycle risk (CCR) score, which combines the University of California, San Francisco's Cancer of the Prostate Risk Assessment (CAPRA) and the cell cycle progression (CCP) molecular score, has been validated to be prognostic of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::731bca966a17616d1116388a05f04a30
https://pubmed.ncbi.nlm.nih.gov/36621237
https://pubmed.ncbi.nlm.nih.gov/36621237